# COMPETENT AND FAIR chemical manufacturer in the pharmaceutical industry



#### Who we are



**CF Pharma Ltd.,** Hungary is an independent company, being part of the family Schneider owned company group structure, with pharmaceutical intermediate and API (active pharmaceutical ingredient) development and **manufacturing** capabilities of small molecules.



**Pátriapharma Ltd.,** Hungary is dedicated to provide **Business development** service within the group.



Patriapharma Japan, is the Japanese representative office







### Our strengths











**EU GMP** 

**Brazilian GMP** 

Japanese GMP

**ESG** mindset

**Backwards** integration







**Technical package or Drug Master File** preparation



High level of regulatory & customer relations management



Lab-to-ton scale comprehensive activities



Teamwork, family atmosphere







DR. GÉZA SCHNEIDER, CEO of CF Pharma – attended the Chemical Faculty of Eötvös Loránd University, Budapest where he received his Master degree and from the Faculty of Chemical Engineering of the Technical University of Budapest where received his PhD. From 1966 to 1986 he worked for the Institute of Drug Research where he became Head of the Research of the team. In 1986 he changed for Egis Pharmaceutical Works where he became the Head of Research department. He worked there for 9 years when he undertook CEO position at FIVE COOP – under his leadership this company became the first synthetic source for Melatonin – and later, in 1996 he founded CF Pharma. He has 6 research papers and 18 patents. He was awarded as an excellent inventor in 1985 and became the member of the American Chemical Society in 2008.



ZITA SCHNEIDER, CEO of PatriaPharma, and CF Pharma – attended the Chemical Faculty of Eötvös Loránd University, Budapest where she received her Master degree as a chemist. Since she joined the family company in 2003 she worked in various positions: started as QC assistant, then production technologist, head of regulatory affairs, head of quality assurance and later as head of quality. In this last 17 years she participated several GMP related trainings, participated and led internal and external quality audits. Since the establishment of Patriapharma she is also involved in the sales activities. Zita has returned in 2019 from Singapore where she attended INSEAD executive program and strengthened the Asian connections. Since 2020 she is the second generation CEO in the companies.







## **Organizational structure**










# **HISTORY**















# THE SITE
















### Our site

AREA OF THE SITE	152 500 m <sup>2</sup>
NUMBER OF PLANTS	1
NUMBER OF CLEAN ROOMS	2
TOTAL REACTOR VOLUME	130 m <sup>3</sup>
R&D LABORATORIES	4
QUALITY CONTROL LABORATORIES	3
AREA FOR EXPANSION	60.000 – 100.000 m <sup>2</sup>

AREA FOR EXPANSION with LICENCE FOR CHEMICAL ACTIVITY

PRODUCTION PLANT



WEIGHING ROOM and FUTURE INTEGRATED WAREHOUSE MANAGEMENT & LABORATORIES







#### **Process Patents & Know-hows**

#### **Process Patents:**


LAMOTRIGINE I.	LAMOTRIGINE II.	BICALUATMIDE I.	BICALUATMIDE II.	ROPINIROLE	TOPIRAMATE	LERCANIDIPINE	PRAMIPEXOLE
WO 03008393	HU 0103073	WO 03097590	WO 0134563	EP1568689	EP1627881	EP1860102	EP1878721l
EP1311492		EP1506170	P1669347	US 2005/0191338	US 2006/0040874		
US6683182		US 2005/0033082					




#### **Know-hows:**

Atracurium besylate

Cisatracurium besylate



Cabergoline



Biperiden HCl and base







Draduate	CAS number Therapeutic area	GMP	QUALITY		REGULATORY		,	Chambard analysis size	
Products		merapeutic area	certificate	Ph. Eur.	USP	СЕР	J-DMF	EU DMF	Standard package size
ATRACURIUM BESYLATE	64228-81-5	Muscle relaxants	<b>/</b>	<u> </u>		<u> </u>	N/A		0.5 kg, 1 kg, 5 kg
BIPERIDEN BASE	514-65-8	Anti-Parkinson drug	<b>/</b>	*	**	_	<b>\</b>	<u></u>	0.1 kg, 0.2 kg, 0.5 kg, 1 kg, 3 kg, 5 kg
BIPERIDEN HCI	1235-82-1	Anti-Parkinson drug	<b>/</b>	<b>\</b>	-	<u> </u>	<b>/</b>	<u></u>	1 kg, 5 kg
CABERGOLINE	81409-90-7	Prolactine Inhibitors	<b>\</b>	<b>\</b>	<u> </u>	in progress	-	<u> </u>	0.1 kg, 0.2 kg, 0.5 kg, 1 kg
CISATRACURIUM BESYLATE	96945-42-8	Muscle relaxants	<b>\</b>				N/A		0.5 kg, 1 kg, 2 kg, 3 kg, 4 kg, 5 kg

IN DEVELOPMENT: DROPERIDOL, NEFOPAM, PHENYLTOLOXAMIN APIS

Other qualities and DMFs are available
\* based on Biperiden HCI monograph \*\* based on USP 39

#### **CF Pharma Ltd.**

Where chemistry works

- GMP certified European API manufacturer
- Regularly inspected by Competent Health Authorities (EU/HU)
- PMDA (Japan) accreditation since 2013
- API Registration Worldwide (e.g. ANVISA, Cofepris, EMA, KFDA)
- Approved DMFs all over the World







#### **Technology**

We have strong skills in small molecule chemistry and process development with proven experience in handling complex, hazardous and unique chemistry including controlled substances. This allows us to be a partner of choice in the research & development of difficult-to-make molecules.

As a result of R&D activities more than 25 API manufacturing processes have been developed for small and intermediate scale production.

We undertake contract development and contract manufacturing of small molecules from mg to ton scale.









Lab Scale: 0.5 – 500 grams

Pilot Scale: 0.5 – 10 kgs

Plant Scale: 50-1200 kgs

Temperature range: (-)20°C upto 160°C

Pressure range: (-)0.95 Bar upto 5 Bar



API ROS developed: 25

Intermediate synthesis for 23 years

API synthesis for 19 years







# Representative reaction types and batch sizes


REACTION TYPE	REAGENTS	KG/BATCH
von Braun reaction	Bromocyan	3
Reduction	Pd/C, Hydrogen	125
Chlorination	Chlorine gas	150
Cyclization	anhydr. FeCl <sub>3</sub>	150
Friedel-Crafts Reaction	AICI <sub>3</sub> / NaCl	155
Monomerization	Dicyclopentadiene	200
Hantzsch reaction	Amino-crotonic acid methyl ester	200
Cyanation	Sodium cyanide	200
Reduction	Pd/C Formic acid, Ammonium salt	220
Pinner Reaction	HCI/EtOH, NH <sub>3</sub>	230
Chlorosulphonation	Clorosulfonic acid	250
Grignard Reaction	Phenyl-Mg-Chloride, Methyl-Mg-Chloride	2-400
Sulfon formation	4-fluoro- benzosulfonylcloride	400
Reduction	Na-Borohydride	400
Sulfamoylation	Clorosulfonyl isocyanate	500
Nitration	Nitric Acid	800
Hydroxymethylation	Formaldehyde/sulfuric acid-sulfurtrioxide	800
Bromination	Bromine	1000







#### **Portfolio & Project management**









# THE INFRASTRUCTURE







# Main production equipment – commercial scale

COMMERCIAL SCALE	TYPE	NUMBER	VOLUME RANGE	TYPE
Reactor	Glass lined	33	100 – 16000 L Total: 94 000 L	De Dietrich, Pfaudler, Lampart
	Stainless steel	7	250 – 10000 L Total: 31 000 L	Custom made
Centrifuge	Stainless steel	8	600 – 1250 mm	OMNR, BVGC
Dryer	Stainless steel	1	3000 L	Hosokawa
Filters	Stainless steel	8	5 – 100 L	Sparkler, Pall









### **Clean area**

COMMERCIAL SCALE	TYPE	NUMBER	VOLUME RANGE	ТҮРЕ
Crystallizer	Glas lined	1	1250 L	Pfaudler
Centrifuge	Stainless steel	1	800 mm	Krauss Maffei
Dryer	Stainless steel	3	150 – 1000 L	Pink, Kiskun-Meridian
Hammer mill	Stainless steel	1	5 – 15 kg/h	Micropure
Air jet mill	Stainless steel	1	2 – 10 kg/h	Kiskun-Meridian









#### Message from our CEOs

"Our approach to ESG reflects intention to become "force for good", to carry-out actions inspired by the genuine concern for others. Our family business although far not the biggest aims to target goals set by mindful giants: minimizing the impact of our operations on the planet, advance ethics, health and equity through our business and products."





**Géza Schneider CEO** 

Zita Schneider

**Zita Schneider CEO** 







#### **ENVIRONMENTAL**

- Full implemention of BAT
- Zero tolerance of new contaminants
- Decrease the carbon footprint of our activity
- **Biodiversity program**



#### **SOCIAL**

- Contributing to the development of science and initiatives to improve access to medicines
- Diversity & inclusion
- **Fight against Social Chemophobia** (support and advocacy)
- Local community contribution
- Health, safety and welfare of employees



#### **GOVERNANCE**

- Family atmosphere
- **Training and development of** employees & suppliers
- Fair and transparent corporate activities
















Brought To You By: | SCRIP



In Association With





# **Engagement in environment-friendly activities**
















#### PÁTRIAPHARMA Ltd.

Tax number: 12422108-2-43 | D-U-N-S number: 366733274

The financial risk of developing a business relationship with the enterprise is very low i.e. it is one of the exceptional Hungarian companies that have complied with the strictest conditions set by the Dun & Bradstreet international rating system.

Taking hundreds of variables into account, on the basis of stipulated standards and incorporating country-specific features, those enterprises are selected for which the risk of concluding business transactions is the lowest, i.e. they are among the most financially stable enterprises in Hungary.



Neeraj Sahai 🥛 🌑 President, Dun & Bradstreet International

17 November 2023

000000

dun & bradstreet











**High Creditworthy** 

Gold 2022

#### PÁTRIAPHARMA Ltd.

Tax number: 12422108-2-43 | D-U-N-S number: 366733274

The **financial risk** of developing a business relationship with the enterprise is very low i.e. it is one of the exceptional Hungarian companies that have complied with the strictest conditions set by the Dun & Bradstreet international rating system.

Taking hundreds of variables into account, on the basis of stipulated standards and incorporating country-specific features, those enterprises are selected for which the risk of concluding business transactions is the lowest, i.e. they are among the most financially stable enterprises in Hungary.



Neeraj Sahai 🛑 🌑 President, Dun & Bradstreet International

3 November 2022

dun & bradstreet